for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Elekta AB (publ)

EKTAb.ST

Latest Trade

124.20SEK

Change

0.15(+0.12%)

Volume

584,711

Today's Range

123.40

 - 

125.25

52 Week Range

97.12

 - 

143.00

As of on the Stockholm Stock Exchange ∙ Minimum 15 minute delay

Pricing

Previous Close
124.05
Open
123.60
Volume
584,711
3M AVG Volume
31.39
Today's High
125.25
Today's Low
123.40
52 Week High
143.00
52 Week Low
97.12
Shares Out (MIL)
382.03
Market Cap (MIL)
45,778.59
Forward P/E
30.10
Dividend (Yield %)
1.45

Next Event

Q2 2020 Elekta AB (publ) Earnings Release

Latest Developments

More

Elekta Awarded Sole Source Agreement With Premier

Elekta Signs Distribution Agreement With DOSIsoft

Elekta Acquires ProKnow Systems

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Elekta AB (publ)

Elekta publ AB is a Sweden-based human care company that develops and sells clinical solutions for the treatment of cancer and brain disorder. The Company offers and develops systems for radiation therapy and radio-surgery, as well as software systems that enhance workflow efficiency throughout the entire spectrum of cancer care. The Company has four product areas: Elekta Neuroscience, which develops solutions for the diagnosis and treatment of neurological diseases; Elekta Oncology, which creates clinical solutions for radiation therapy, such as linear accelerators, integrated imaging systems and clinical solutions for patient positioning and immobilization; Elekta Brachytherapy, which is engaged in the treatment of cancer through internal radiation, and Elekta Software, which develops software solutions for patient information, workflow management and treatment planning in oncology. The Company owns the service business of Asesores Electronicos Especializados SA de CV (AEESA).

Industry

Medical Equipment & Supplies

Contact Info

Box 7593

+46.8.58725400

https://www.elekta.com/

Executive Leadership

Laurent Leksell

Chairman of the Board

Richard Hausmann

President, Chief Executive Officer, Member of the Executive Management

Gustaf Salford

Chief Financial Officer, Member of the Executive Management

Steven Wort

Chief Operating Officer, Member of the Executive Management

Jonas Bolander

General Counsel, Executive Vice President, Member of the Executive Management

Key Stats

2.53 mean rating - 15 analysts
Sell
Hold
Buy
Revenue (MM, SEK)

2017

10.7K

2018

11.3K

2019

13.6K

2020(E)

15.5K
EPS (SEK)

2017

1.690

2018

2.880

2019

3.140

2020(E)

4.126
Price To Earnings (TTM)
40.24
Price To Sales (TTM)
3.28
Price To Book (MRQ)
6.05
Price To Cash Flow (TTM)
20.42
Total Debt To Equity (MRQ)
73.65
LT Debt To Equity (MRQ)
57.99
Return on Investment (TTM)
9.40
Return on Equity (TTM)
5.05

Latest News

Latest News

RPT-BRIEF-Elekta Q4 EBIT SEK 755 Million, Above Estimates

* Q4 GROSS ORDER INTAKE SEK 5.40 BILLION VERSUS SEK 4.66 BILLION YEAR AGO

UPDATE 1-Elekta Q4 adjusted operating profit below forecasts, dividend higher

Swedish radiation therapy equipment maker Elekta on Friday reported below-forecast earnings for its fiscal fourth quarter, but proposed a higher dividend than expected.

BRIEF-Apollo Hospitals Group chooses Elekta for new proton center

* APOLLO HOSPITALS GROUP CHOOSES ELEKTA'S MOSAIQ FOR NEW PROTON CENTER Source text for Eikon: Further company coverage: (Reporting by Stockholm Newsroom)

BRIEF-Elekta Makes Strategic Investment In PalabraApps

* ELEKTA EXPANDS THE MOSAIQ ECOSYSTEM OF COMPLEMENTARY APPLICATIONS WITH STRATEGIC INVESTMENT IN PALABRAAPPS

BRIEF-Elekta wins government tender in Mexico

* ELEKTA STRENGTHENS PRESENCE IN MEXICO WITH GOVERNMENT TENDER FOR RADIATION THERAPY TECHNOLOGY

BRIEF-Elekta has won order in ‍Egypt, was booked in Q3 ​

* SAYS EGYPT HAS AGAIN CHOSEN ELEKTA tO EQUIP ITS MINISTRY OF HEALTH HOSPITALS, INCLUDING NATIONAL CANCER INSTITUTE (NCI) IN CAIRO

UPDATE 2-Elekta shares jump on forecast-beating Q3 earnings

Swedish radiation therapy equipment maker Elekta on Friday reported above-forecast earnings and order intake for its fiscal third quarter, sending shares higher and outweighing a cut margin forecast for the full year.

BRIEF-Elekta AB Q3 profit and orders top forecasts, cuts full-year margin target

* Q3 GROSS ORDER INTAKE AMOUNTED TO SEK 3,833 M (3,653), AN INCREASE OF 9 PERCENT BASED ON CONSTANT EXCHANGE RATES AND 5 PERCENT IN SEK

BRIEF-Bolivia buys linear accelerators from Elekta

* BOLIVIAN GOVERNMENT INVESTS IN STATE-OF-THE-ART CANCER CARE FROM ELEKTA

BRIEF-Elekta's Gamma Knife system cleared for use by China

* ELEKTA'S LEKSELL GAMMA KNIFE ICON RADIOSURGERY SYSTEM CLEARED FOR USE IN CHINA Source text for Eikon: Further company coverage: (Reporting by Stockholm Newsroom)

BRIEF-Elekta signs $29 mln deal with the Ottawa Hospital

* THE OTTAWA HOSPITAL ACQUIRES SEVERAL ELEKTA VERSA HD DEVICES FOR ADVANCED CANCER TREATMENT

BRIEF-Elekta reaches agreement in dispute with Stockholm County Council

* ELEKTA AND STOCKHOLM COUNTY COUNCIL AGREE ON CONSTRUCTIVE WAY FORWARD

UPDATE 1-Elekta delays order target for new radiation therapy machine

Sweden's Elekta pushed back its order target for a new radiation therapy machine which is meant to drive its future sales growth on Thursday as it reported higher quarterly core earnings than expected.

BRIEF-Elekta CEO: Unity radiation therapy system a 2018 sales driver

Elekta AB CEO Richard Hausmann and CFo Gustaf Salford in a conference call with analysts and media:

Elekta postpones order target for new flagship product Unity

Swedish radiotherapy gear maker Elekta on Thursday pushed back its target for order bookings of its new flagship radiation therapy machine Unity as it posted higher quarterly core earnings, but lower order intake, than expected.

BRIEF-Elekta Q2 core profit beat expectations, orders lag

* SAYS OUR TARGETS FOR YEAR ARE CLEAR - WE WILL DELIVER PROFITABLE GROWTH AND REACH AN EBITA MARGIN EXCEEDING 20 PERCENT THROUGH GROWTH AND OUR WORK WITH CONTINUOUS OPERATIONAL IMPROVEMENTS

BRIEF-Elekta signs £22 mln agrement with UK's National Health Service

* UK'S NATIONAL HEALTH SERVICE SIGNS GBP 22 MILLION AGREEMENT FOR ELEKTA CANCER TREATMENT SYSTEMS

BRIEF-21St century oncology chooses Elekta for replacement of radiation therapy devices

* Elekta announces that 21st Century Oncology, the largest radiation oncology provider in the U.S., will replace several of its existing linear accelerators, as well as treatment planning software and oncology information systems, with advanced cancer treatment solutions...

BRIEF-Elekta says CE mark for Unity is expected during first half of 2018

* Elekta has decided to add additional functional imaging capabilities to its MR-linac (Unity) and to spend more time on validating its linac control system

BRIEF-Mclaren Health Care and Elekta mutually terminate long-term agreement

* Mclaren Health Care and Elekta have mutually agreed to terminate their long-term agreement.

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up